Growth hormone deficiency secondary prevention: Difference between revisions
Usama Talib (talk | contribs) Created page with "__NOTOC__ {{Growth hormone deficiency}} {{CMG}}; {{AE}} ==Overview== *There are no established measures for the secondary prevention of [disease name]. OR *Effective measure..." |
|||
| (5 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Growth hormone deficiency}} | {{Growth hormone deficiency}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{MAD}} | ||
==Overview== | ==Overview== | ||
Patients who are receiving growth hormone therapy should be followed up 2-4 times per year. [[Growth]] rate usually increases during the first year of treatment, with an average increase of 8-10 cm/year. A slow [[Growth|growth rate]] more than expected should be investigated to exclude other causes such as [[hypothyroidism]] or [[inflammatory bowel disease]]. | |||
== | == Growth hormone deficiency secondary prevention == | ||
Effective measures for the secondary prevention of growth hormone deficiency include: | |||
* Patients who are receiving growth hormone therapy should be followed up 2-4 times per year. | |||
* | * The most important reasons for follow-up are to monitor [[growth]] progress and to adjust [[growth hormone]] dosage. | ||
* | * Follow-up may also be needed to assure patient compliance with the treatment. | ||
* Growth rate usually increases during the first year of treatment, with an average increase of 8-10 cm/year. | |||
* Progressive [[growth]] slows over the next several years. | |||
* A slow [[Growth|growth rate]] more than expected should be investigated to exclude other causes such as [[hypothyroidism]] or [[inflammatory bowel disease]]. | |||
==References== | ==References== | ||
Latest revision as of 19:46, 27 October 2017
|
Growth hormone deficiency Microchapters |
|
Differentiating Growth hormone deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Growth hormone deficiency secondary prevention On the Web |
|
American Roentgen Ray Society Images of Growth hormone deficiency secondary prevention |
|
Risk calculators and risk factors for Growth hormone deficiency secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]
Overview
Patients who are receiving growth hormone therapy should be followed up 2-4 times per year. Growth rate usually increases during the first year of treatment, with an average increase of 8-10 cm/year. A slow growth rate more than expected should be investigated to exclude other causes such as hypothyroidism or inflammatory bowel disease.
Growth hormone deficiency secondary prevention
Effective measures for the secondary prevention of growth hormone deficiency include:
- Patients who are receiving growth hormone therapy should be followed up 2-4 times per year.
- The most important reasons for follow-up are to monitor growth progress and to adjust growth hormone dosage.
- Follow-up may also be needed to assure patient compliance with the treatment.
- Growth rate usually increases during the first year of treatment, with an average increase of 8-10 cm/year.
- Progressive growth slows over the next several years.
- A slow growth rate more than expected should be investigated to exclude other causes such as hypothyroidism or inflammatory bowel disease.